In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase
- 26 April 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (9) , 4065-4080
Abstract
An integrated computational approach to drug discovery was used to identify novel potential inhibitors of the native and mutant (T315I) Bcr-Abl tyrosine kinase, the enzyme playing a key role in the pathogenesis of chronic myeloid leukemia (CML). This approach included i) design of chimeric molecules based on the 2-arylaminopyrimidine fragment, the main pharmacophore of the Abl kinase inhibitors imatinib and nilotinib used in the clinic for the CML treatment, ii) molecular docking of these compounds with the ATP-binding site of the native and mutant Abl kinase, iii) refinement of the ligand-binding poses by the quantum chemical method PM7, iv) molecular dynamics simulations of the ligand/Abl complexes, and v) prediction of the ligand/Abl binding affinity in terms of scoring functions of molecular docking, machine learning, quantum chemistry, and molecular dynamics. As a result, five top-ranking compounds able to effectively block the enzyme catalytic site were identified. According to the data obtained, these compounds exhibit close modes of binding to the Abl kinase active site that are mainly provided by hydrogen bonds and multiple van der Waals contacts. The identified compounds show high binding affinity to the native and mutant Abl kinase comparable with the one calculated for the FDA-approved kinase-targeted inhibitors imatinib, nilotinib, and ponatinib used in the calculations as a positive control. The results obtained testify to the predicted drug candidates against CML may serve as good scaffolds for the design of novel anticancer agents able to target the ATP-binding pocket of the native and mutant Abl kinase. Communicated by Ramaswamy H. SarmaKeywords
Funding Information
- State Program of Scientific Research “Convergence 2025”
This publication has 54 references indexed in Scilit:
- Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parametersJournal of Molecular Modeling, 2012
- Rational Approaches to Improving Selectivity in Drug DesignJournal of Medicinal Chemistry, 2012
- NNScore 2.0: A Neural-Network Receptor–Ligand Scoring FunctionJournal of Chemical Information and Modeling, 2011
- BINANA: A novel algorithm for ligand-binding characterizationJournal of Molecular Graphics and Modelling, 2011
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- A census of human cancer genesNature Reviews Cancer, 2004
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003
- Comparison of simple potential functions for simulating liquid waterThe Journal of Chemical Physics, 1983